Acknowledgement to our reviewers
Good and timely peer review is absolutely essential for the success of the Journal of Hepatology. We are therefore extremely grateful for the support of so many colleagues who have dedicated their time this year. These reviewers have evaluated the research that was submitted to the journal, and shared their insights about the papers strengths and weaknesses. This has both enabled us to make the right editorial decisions, and helped our authors to further improve their work. Out of necessity, the role of the reviewer is anonymous and therefore, may go unnoticed at times. (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 14, 2018 Category: Gastroenterology Source Type: research

EASL-AASLD HBV endpoints, London, United Kingdom, 2019
(Source: Journal of Hepatology)
Source: Journal of Hepatology - December 14, 2018 Category: Gastroenterology Source Type: research

Editorial Board
(Source: Journal of Hepatology)
Source: Journal of Hepatology - December 14, 2018 Category: Gastroenterology Source Type: research

EASL short-term training fellowship - Andrew K. Burroughs
(Source: Journal of Hepatology)
Source: Journal of Hepatology - December 14, 2018 Category: Gastroenterology Source Type: research

The International Liver CongressTM, Vienna, Austria, 2019
(Source: Journal of Hepatology)
Source: Journal of Hepatology - December 14, 2018 Category: Gastroenterology Source Type: research

EASL clinical school: Modern dilemmas in liver transplantation, University of Birmingham, United Kingdom, 2019
(Source: Journal of Hepatology)
Source: Journal of Hepatology - December 14, 2018 Category: Gastroenterology Source Type: research

EASL basic school: Metabolism, immunity and liver disease, Munich, Germany, 2019
(Source: Journal of Hepatology)
Source: Journal of Hepatology - December 14, 2018 Category: Gastroenterology Source Type: research

Contents
(Source: Journal of Hepatology)
Source: Journal of Hepatology - December 14, 2018 Category: Gastroenterology Source Type: research

JHEP at a glance (January 2019)
(Source: Journal of Hepatology)
Source: Journal of Hepatology - December 14, 2018 Category: Gastroenterology Source Type: research

EASL HCC Summit 2019, Lisbon, Portugal
(Source: Journal of Hepatology)
Source: Journal of Hepatology - December 14, 2018 Category: Gastroenterology Source Type: research

From the Editor ’s Desk
Identifying environmental factors associated with the development of non-alcoholic fatty liver disease (NAFLD) is a matter of intense research. Lactation has been shown to exert beneficial effects in both the child and the mother. Among its beneficial effects, lactation is known to lower triglycerides and to increase insulin sensitivity. In this issue of the Journal, Ajmera et al. studied if longer duration of lactation is associated with a lower prevalence of NAFLD in women. The study included a large cohort of young women who delivered one post-baseline birth or more and were followed for 25  years. (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 14, 2018 Category: Gastroenterology Authors: Richard Moreau, Ramon Bataller, Thomas Berg, Sophie Lotersztajn, Jessica Zucman-Rossi, Rajiv Jalan Tags: Editorial Desk Source Type: research

Time to recurrence, but not recurrence-free survival, should be the endpoint of predicting early recurrence after HCC resection
In this study, gender, preoperative albumin-bilirubin (ALBI) grade, preoperative alpha-fetoprotein (AFP) level, tumor size, tumor number, and microvascular invasion were revealed as independent predictors associated with early recurrence after resection of hepatocellular carcinoma (HCC). Using these independent predictors, the authors developed and validated 2 models for predicting early recurrence, i.e., the preoperative model (ERASL-pre) and the postoperative model (ERASL-post). (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 13, 2018 Category: Gastroenterology Authors: Wen-Tao Yan, Bing Quan, Hao Xing, Meng-Chao Wu, Tian Yang Tags: Letter to the Editor Source Type: research

Predicting early hepatocellular carcinoma recurrence after resection: A comment for moving forward
Tumour recurrence, which occurs in 70% of patients with hepatocellular carcinoma (HCC) within 5  years after hepatic resection, is a major cause of post-resection death.1 This recurrence can be true recurrence (intrahepatic metastases), which occurs sooner than 2 years later, or it can be due to the development of de novo tumours at least 2 years later. Despite this high rate of tumour r ecurrence, no anti-recurrence adjuvant therapies are currently recommended by the European Association for the Study of the Liver (EASL)1 or the American Association for the Study of Liver Diseases (AASLD). (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 13, 2018 Category: Gastroenterology Authors: Xiao-Ying Zhang, Jie Ou, Jia-Yi Chen, Wen-Wu Li Tags: Letter to the Editor Source Type: research

Toward the universal scoring system in treatment for patients with hepatocellular carcinoma
With great interest, we read the article written by Chan et al. in a recent issue of “Journal of Hepatology”.1 The authors attempted to develop a new set of preoperative and postoperative scoring systems (ERASL) to predict the outcomes of hepatectomy for hepatocellular carcinoma (HCC), using a statistical approach and validating its prognostic utility in a large international co hort. Their preoperative score demonstrated decent statistical discrimination for 2-year recurrence-free survival (RFS) in their external validation cohort (C-index 0.601–0.672). (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 13, 2018 Category: Gastroenterology Authors: Jiro Kusakabe, Daniel J. Firl, Kazunari Sasaki Tags: Letter to the Editor Source Type: research

A serum protein factor mediates maturation and apoB-association of HCV particles in the extracellular milieu
Hepatitis C virus (HCV) infection is a major cause of chronic liver diseases worldwide. Although recent direct antiviral agents (DAA) can now cure most patients, it remains major challenges in basic, translational and clinical research[1]. As DAAs are only curative, the development of a protective vaccine remains an important goal; yet, this requires deeper knowledge of HCV particles structure. Indeed, HCV virion exhibits unusually heterogeneous particles in morphology, size and properties[2], as immunocapture of its surface proteins revealed particles of 50-80nm without symmetrical arrangement[3 –6]. (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 13, 2018 Category: Gastroenterology Authors: Sol ène Denolly, Christelle Granier, Nelly Fontaine, Bruno Pozzetto, Thomas Bourlet, Maryse Guérin, François-Loïc Cosset Source Type: research

Platelet-Derived Growth Factor-D Enables Liver Myofibroblasts to Promote Tumor Lymphangiogenesis in Cholangiocarcinoma
Cholangiocarcinoma (CCA) originates from the intrahepatic or extrahepatic bile ducts and unfortunately, carries a very poor prognosis. [1] Despite of its increasing incidence, effective treatment options for CCA are scarce and limited to surgical resection or liver transplantation in few highly selected patients. [1] Less than one third of patients are eligible for curative surgery at the time of diagnosis due to a proclivity for early lymph node metastatization. [1,2] Although mechanisms promoting CCA invasiveness are still unclear, [3] the lymphatic vessels that develop within the tumor provide an important initial route...
Source: Journal of Hepatology - December 13, 2018 Category: Gastroenterology Authors: Massimiliano Cadamuro, Simone Brivio, Joachim Mertens, Marta Vismara, Anja Moncsek, Chiara Milani, Christian Fingas, Maria Cristina Malerba, Giorgia Nardo, Luigi Dall'Olmo, Eleonora Milani, Valeria Mariotti, Tommaso Stecca, Marco Massani, Carlo Spirli, Ro Source Type: research

Intraductal Papillary Neoplasm of the Bile Duct: Assessment of Invasive Carcinoma and Long-Term Outcomes using MRI
Intraductal papillary neoplasm of the bile duct (IPNB) is characterized by a papillary or villous biliary neoplasm covering delicate fibrovascular stalks and a histological spectrum ranging from benign disease to invasive malignancy.[1,2] According to the 2010 World Health Organization classification, IPNB can be classified into the following three histologic grades: IPNB with low- or intermediate-grade intraepithelial neoplasia, IPNB with high-grade intraepithelial neoplasia, and IPNB with an associated invasive carcinoma. (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 13, 2018 Category: Gastroenterology Authors: Sunyoung Lee, Myeong-Jin Kim, Sohee Kim, Dongil Choi, Kee-Taek Jang, Young Nyun Park Source Type: research

HCMV jogs the ‘memory’ of NK cells in HBV
The treatment paradigm in hepatitis B virus (HBV) is rapidly transforming with many new viral and immune therapies entering the clinical trial pipeline. Although many of the immune targets focus on restoration of the exhausted virus-specific T cell response1 an increasing body of work makes a case for natural killer (NK) cell-based immune therapies and vaccines.2 Advances in NK cell biology have revealed that these ‘innate’ cells may also possess adaptive features. These cells ‘sitting-on-the-fence’ of innate-adaptive immunity, undergo significant changes in their repertoire during differentiation. ...
Source: Journal of Hepatology - December 11, 2018 Category: Gastroenterology Authors: Upkar S. Gill, Lucy Golden-Mason Tags: Editorial Source Type: research

The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention
Liver cancer is a common lethal malignancy afflicting in excess of 1 million people and caused 800,000 deaths in 2016 worldwide.[1] It has been well documented that the incidence of liver cancer varies considerably across the world, with the highest incidence observed in East Asia. In contrast, the incidence in America is nearly five- to ten-folds lower than the incidence observed in East Asia.[2] Recent decreases in the incidence of liver cancer have been reported in China and Japan.[3 –5] However, newly diagnosed cases and the age standardized incidence rate of liver cancer have increased at global level during the...
Source: Journal of Hepatology - December 10, 2018 Category: Gastroenterology Authors: Zhenqiu Liu, Yanfeng Jiang, Huangbo Yuan, Qiwen Fang, Ning Cai, Chen Suo, Li Jin, Tiejun Zhang, Xingdong Chen Source Type: research

Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with nonalcoholic steatohepatitis
Non-alcoholic steatohepatitis (NASH), a severe form of non-alcoholic fatty liver disease (NAFLD), represents a large and growing public health concern that is increasingly contributing to the rising prevalence of cirrhosis and hepatocellular carcinoma globally[1,2]. Currently, there is no approved drug for NASH, which is projected to be the leading indication for liver transplantation in the next decade[3]. The pathogenesis of NASH is complex, and it is hypothesized that toxic lipid species or intermediates may inflict hepatocyte injury[4]. (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 7, 2018 Category: Gastroenterology Authors: Mary E. Rinella, James F. Trotter, Manal F. Abdelmalek, Angelo H. Paredes, Margery A. Connelly, Mark J. Jaros, Lei Ling, Stephen J. Rossi, Alex M. DePaoli, Stephen A. Harrison Source Type: research

Serum Hepatitis B core-related antigen (HBcrAg) correlates with covalently-closed circular DNA transcriptional activity in chronic hepatitis B patients
The development of novel antiviral agents and immunomodulatory approaches to cure chronic HBV infection requires new biomarkers capable to reflect the intrahepatic activity of the virus and CHB stages and define new meaningful treatment endpoints. Indeed, there is an unmet need for standardized assays able to provide mechanistic insights into the effects of the novel antiviral and immuno-modulatory agents and to assess treatment efficacy[1]. (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 7, 2018 Category: Gastroenterology Authors: Testoni Barbara, Leboss é Fanny, Scholtes Caroline, Berby Françoise, Miaglia Clothilde, Subic Miroslava, Loglio Alessandro, Facchetti Floriana, Lampertico Pietro, Levrero Massimo, Zoulim Fabien Source Type: research

Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis
Hepatocellular carcinoma (HCC) is among the most aggressive cancers, with an increasing incidence, and few therapeutic options[1]. The exceptional investments on -omics studies over the last decade have unveiled not only an impressive list of alterations, but also a high degree of molecular heterogeneity between HCC patients[2,3]. The uniqueness of HCC in its alterations and heterogeneity may explain how treatments effective in other cancers have largely failed when applied to HCC[4]. Such context challenges the interpretation of -omics data, with the necessity to: 1) determine which of these alterations are functionally r...
Source: Journal of Hepatology - December 5, 2018 Category: Gastroenterology Authors: Yannan Fan, Sehrish K. Bazai, Fabrice Daian, Maria Arechederra, Sylvie Richelme, Nuri A. Temiz, Annie Yim, Bianca H. Habermann, Rosanna Dono, David A. Largaespada, Flavio Maina Source Type: research

Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: a phase III STAH trial
Primary liver cancer, including hepatocellular carcinoma (HCC), is the fifth and second commonest cancer and cause of cancer-related mortality, respectively, worldwide.[1] HCC prognosis remains poor owing to underlying chronic liver disease, late diagnosis, and frequent recurrence-progression after treatment; many patients with HCC are diagnosed at advanced stages.[2,3] (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 5, 2018 Category: Gastroenterology Authors: Joong-Won Park, Yoon Jun Kim, Do Young Kim, Si-Hyun Bae, Seung Woon Paik, Youn-Jae Lee, Hwi Young Kim, Han Chu Lee, Sang Young Han, Jae Youn Cheong, Oh Sang Kwon, Jong Eun Yeon, Bo Hyun Kim, Jaeseok Hwang Source Type: research

8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)
In contrast to genotype 1, genotype 4 hepatitis C (HCV) infections are more often found in Central Africa and the Middle East with the highest prevalence in Egypt.1 As the initial budget impact of HCV treatment with direct-acting antivirals (DAAs) can be substantial for countries with a high HCV prevalence,2 shortening treatment duration could help in reaching the World Health Organization ’s HCV elimination goals3 by lowering costs and expanding access.4 The most recent EASL guideline suggests 8 weeks of therapy with sofosbuvir/ledipasvir (SOF/LDV) as an option for treatment-naive non-cirrhotic patients with chron...
Source: Journal of Hepatology - December 4, 2018 Category: Gastroenterology Authors: Anne Boerekamps, Thomas Vanwolleghem, Marc van der Valk, Guido E. van den Berk, Marjo van Kasteren, Dirk Posthouwer, Anthonius S.M. Dofferhoff, Bart van Hoek, Dewkoemar Ramsoekh, Jelle Koopsen, Janke Schinkel, Eric Florence, Joop E. Arends, Bart J. Rijnde Tags: Letter to the Editor Source Type: research

Reply to: “Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?”
We thank Riveiro-Barciela et al. for their interest in our paper “Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors”.1 They reported the case of a patient who developed grade 2 hepatitis under first line treatment with nivolumab (anti-PD-1) and dioxygenasel inhibitor for a metastatic melanoma. The hepatitis im proved with corticosteroid therapy. Because of tumor progression a second line treatment with ipilimumab (anti-CTLA4) was administered. She developed fulminant hepatitis induced by ipilimumab and she was treated with corticosteroids and mycophenolate mofet...
Source: Journal of Hepatology - December 4, 2018 Category: Gastroenterology Authors: Eleonora De Martin, Jean-Marie Michot, Barbara Papouin, Stephane Champiat, Olivier Lambotte, Caroline Robert, Aurelien Marabelle, Catherine Guettier, Didier Samuel Source Type: research

Liver transplantation in patients with liver failure related to exertional heatstroke
Exertional heatstroke (EH) is a rare but serious complication that can occur during intense and prolonged physical exercise in a hot and humid climate. It is mainly characterised by hyperthermia higher than 40 °C associated with central neurological disorders. It occurs in individuals who were previously in good health [1].Fig 1. (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 3, 2018 Category: Gastroenterology Authors: Philippe Ichai, Astrid Laurent-Bellue, Christophe Camus, David Moreau, Mathieu Boutonnet, Faouzi Saliba, Jean Marie Peron, Carole Ichai, Emilie Gregoire, Luc Aigle, Julien Cousty, Alice Quinart, Bertrand Pons, Marc Boudon, Stephane Andr é, Audrey Coilly, Source Type: research

Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?
We read with great interest the recent article by De Martin et al. characterizing the liver injury induced by cancer immunotherapy. Their experience in immune-mediated hepatitis related to checkpoint inhibitors included 16 histologically proven cases after anti-PD-1/PD-L1 or anti-CTLA-4 therapy; in 38%, hepatitis resolved without steroid therapy.1 However, as illustrated by the case recently reported by Bhave et al., immune-mediated hepatitis can be severe and lead to acute liver failure (ALF), with a poor prognosis despite treatment with high steroid doses plus mycophenolate mofetil (MMF). (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 28, 2018 Category: Gastroenterology Authors: Mar Riveiro-Barciela, Eva Mu ñoz-Couselo, Jesús Fernandez-Sojo, Nely Diaz-Mejia, Rafael Parra-López, María Buti Source Type: research

Epidemiology and natural history of hepatitis C virus infection among children and young people
Chronic hepatitis C virus (HCV) infection is a global health burden with an estimated prevalence varying between 0.6%-10% dependent on geographical location and an estimated 71 million people worldwide with chronic infection [1 –3]. In Western Europe, the estimated prevalence is 1.5%-3.5%, but in the UK it is 0.5%. Chronic HCV is associated with increased morbidity and mortality and is a leading cause of end stage liver disease, cirrhosis and liver cancer worldwide [3–6]. Although HCV infection rarely contributes to mo rbidity during childhood, the majority of HCV infected children develop chronic HCV with a li...
Source: Journal of Hepatology - November 26, 2018 Category: Gastroenterology Authors: Line Modin, Adam Arshad, Bryony Wilkes, Jennifer Benselin, Carla Lloyd, William L. Irving, Deirdre A. Kelly Source Type: research

Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: An updated occult HBV infection definition
With great interest, we read the manuscript “Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: a new tool to detect occult infection” by Caviglia et al. published in Journal of Hepatology.1 Using a highly sensitive in-house droplet digital PCR assay (ddPCR) method, the authors indicated that intrahepatic HBV covalently closed circular (cccDNA) was detectable in about half (52%, 27/52) of the defined cases of occult HBV infection (OBI). We wonder whether the pretreatment with plasmid-safe ATP dependent DNase (PSAD) plus double-over-gap cccDNA ‘specific’ primers span...
Source: Journal of Hepatology - November 22, 2018 Category: Gastroenterology Authors: Yongzhen Liu, Wanjia Zeng, Jingyuan Xi, Hui Liu, Hao Liao, Guangxin Yu, Xiangmei Chen, Fengmin Lu Tags: Letter to the Editor Source Type: research

Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring
We read with great interest the Snapshot ‘Treatment of chronic hepatitis C” recently published by Forns and Sarrazin in the Journal of Hepatology.1 The authors defined several special populations which require special attention. We believe, that patients on strong inducing anti-epileptic drugs (AEDs) such as carbamazepine, phenytoin an d phenobarbital are an additional population that requires special attention as treatment of individual cases remains a major challenge.2 Co-administration of direct-acting antivirals (DAAs) with these AEDs is contraindicated as plasma concentrations are markedly reduced2 potenti...
Source: Journal of Hepatology - November 22, 2018 Category: Gastroenterology Authors: Minou van Seyen, Elise J. Smolders, Peter van Wijngaarden, Joost P.H. Drenth, Marjan Wouthuyzen-Bakker, Robert J. de Knegt, Pieter Honkoop, Omar El-Sherif, Angela Colbers, David J. Back, David M. Burger Tags: Letter to the Editor Source Type: research

Evolutionary biology of human hepatitis viruses
Approximately 1.3 million people die annually from viral hepatitis worldwide [1]. These deaths are linked to cirrhosis and hepatocellular carcinoma (HCC) resulting from chronic infections with hepatitis B virus (HBV; 887,000 deaths) and hepatitis C virus (HCV; 399,000 deaths) [2], as well as hepatitis and liver failure resulting from acute infections with hepatitis A virus (HAV; 11,000 deaths) and hepatitis E virus (HEV; 44,000 deaths) [1]. Approximately 5% of HBV-infected persons worldwide are simultaneously infected with hepatitis delta virus (HDV) [1,3]. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 22, 2018 Category: Gastroenterology Authors: Andrea Rasche, Anna-Lena Sander, Victor Max Corman, Jan Felix Drexler Tags: Review Source Type: research

Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in 723 patients with chronic hepatitis C
Chronic infection with hepatitis C virus (HCV) still remains a leading cause of morbidity and mortality worldwide, with more than 70 million individuals infected despite recent improvements in antiviral therapies [1,2]. In the last years, direct-acting antivirals (DAA) have dramatically revolutionized this scenario, since the availability of potent Interferon (IFN)-free regimens have led to an increase in sustained virological response (SVR) rates, especially among those patients who were previously contraindicated to IFN-based antiviral therapies [2,3]. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 22, 2018 Category: Gastroenterology Authors: Roberta D'Ambrosio, Luisa Pasulo, Massimo Puoti, Maria Vinci, Monica Schiavini, Sergio Lazzaroni, Alessandro Soria, Federico Gatti, Barbara Menzaghi, Alessio Aghemo, Francesca Capelli, Maria Grazia Rumi, Lorenzo Morini, Alessia Giorgini, Marie Graciella P Source Type: research

SEC14L2, a lipid-binding protein, regulate HCV replication in culture with inter- and intra- genotype variations
Hepatitis C virus (HCV) is a positive stranded RNA Hepacivirus in the Flaviviridae family. Today, HCV remains an important element in the aetiology of chronic liver disease and according to the World Health Organisation there are estimated 71 million chronically infected patients worldwide [1]. Since the virus discovery in 1989, the development of tools such as a subgenomic replicon system, cell culture adapted variants and highly permissive hepatoma cell lines have enabled researchers to study different aspects of the HCV life cycle. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 22, 2018 Category: Gastroenterology Authors: Rui Costa, Daniel Todt, Francisco Zapatero-Belinch ón, Christian Schenk, Olympia E. Anastasiou, Andreas Walker, Barbara Hertel, Lejla Timmer, Denisa Bojkova, Maren Ruckert, Christoph Sarrazin, Jörg Timm, Volker Lohmann, Michael P. Manns, Eike Steinman, Source Type: research

Only in the darkness can you see the stars: Severe alcoholic hepatitis and higher grades of acute-on-chronic liver failure
We read with interest the recently published study by Serst é et al. in the Journal, as well as the subsequent correspondences by Forrest et al. and the original authors.1,2 Both the study and subsequent correspondences agreed on to 2 important aspects in severe alcoholic hepatitis (SAH) related acute-on-chronic liver failure (ACLF): i) the benefits of cort icosteroids (CS) for SAH in patients with ACLF grades 2 and 3 and ii) the dire need for new clinical trials in this difficult to treat group of patients. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 20, 2018 Category: Gastroenterology Authors: Cyriac Abby Philips, Philip Augustine, Guruprasad Padsalgi, Rizwan Ahamed, Amal Jose, Sasidharan Rajesh Tags: Letter to the Editor Source Type: research

Reply to: “Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: An updated occult HBV infection definition”
Recently, we developed a novel digital droplet PCR (ddPCR) assay for the selective quantitation of intrahepatic HBV covalently-closed-circular DNA (cccDNA), the plasmid-like episome form of HBV DNA that serves as template for all viral RNAs.1 We used this method to determine the prevalence and quantity of HBV cccDNA in individuals with occult HBV infection (OBI) recruited among a cohort of 100 hepatitis B surface (HBsAg)-negative/antibody to hepatitis B core antigen (anti-HBc)-positive liver donors. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 20, 2018 Category: Gastroenterology Authors: Gian Paolo Caviglia, Antonella Olivero, Antonina Smedile Tags: Letter to the Editor Source Type: research

Grand Round: Autoimmune Hepatitis
Autoimmune hepatitis (AIH) is a corticosteroid responsive, autoimmune liver disease arising consequent to immunogenetic and environmental risk factors. The clinical course reflects relapsing and remitting, hepatocyte targeted, immunologic damage, countered by reparative responses to cell injury. Appropriate and timely immunosuppressive therapy drives disease into remission, albeit accompanied by inevitable side effects. Many challenges faced in the clinic reflect practice that must capture a heterogeneous disease presentation, course, and treatment response, as well as treatment tolerability. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 19, 2018 Category: Gastroenterology Authors: Palak J. Trivedi, Stefan G Hubscher, Michael Heneghan, Dermot Gleeson, Gideon M. Hirschfield Tags: Grand Rounds Source Type: research

Editorial Board
(Source: Journal of Hepatology)
Source: Journal of Hepatology - November 15, 2018 Category: Gastroenterology Source Type: research

EASL: Join the community or renew your membership
(Source: Journal of Hepatology)
Source: Journal of Hepatology - November 15, 2018 Category: Gastroenterology Source Type: research

EASL registry grants
(Source: Journal of Hepatology)
Source: Journal of Hepatology - November 15, 2018 Category: Gastroenterology Source Type: research

The International Liver CongressTM, Vienna, Austria, 2019
(Source: Journal of Hepatology)
Source: Journal of Hepatology - November 15, 2018 Category: Gastroenterology Source Type: research

EASL HCC Summit 2019, Lisbon, Portugal
(Source: Journal of Hepatology)
Source: Journal of Hepatology - November 15, 2018 Category: Gastroenterology Source Type: research

Contents
(Source: Journal of Hepatology)
Source: Journal of Hepatology - November 15, 2018 Category: Gastroenterology Source Type: research

JHEP at a glance (December 2018)
(Source: Journal of Hepatology)
Source: Journal of Hepatology - November 15, 2018 Category: Gastroenterology Source Type: research

paid mbp advert paid mbp advert JHEPAT_HBV_181018
(Source: Journal of Hepatology)
Source: Journal of Hepatology - November 15, 2018 Category: Gastroenterology Source Type: research

From the Editor ’s desk.…
Many studies have indicated a beneficial role of albumin in cirrhotic patients, which extends well beyond its fluid expansion effect. Recently, a randomised multicentre study from Italy, the ANSWER study, suggested widespread beneficial effects of repeated administration of albumin to patients with decompensated cirrhosis, including a reduction in mortality. Sol à et al. performed a randomised placebo-controlled study to evaluate the role of long-term administration of midodrine and albumin to patients with decompensated cirrhosis. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 15, 2018 Category: Gastroenterology Authors: Richard Moreau, Ramon Bataller, Thomas Berg, Sophie Lotersztajn, Jessica Zucman-Rossi, Rajiv Jalan Tags: Editorial Desk Source Type: research

paid mbp advert paid mbp advert JHEPAT_BIRMING_02_MAY_19
(Source: Journal of Hepatology)
Source: Journal of Hepatology - November 15, 2018 Category: Gastroenterology Source Type: research

paid mbp advert JHEPAT_MUNICH_181018
(Source: Journal of Hepatology)
Source: Journal of Hepatology - November 15, 2018 Category: Gastroenterology Source Type: research

Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018
The recently published “EASL Recommendations on Treatment of Hepatitis C 2018” are described as “primarily based on evidence from existing publications and presentations at international meetings.” We agree with this approach that prioritizes publically available clinical data from randomized clinical trials over personal experience or preclinical information; however, the current guidelines have overlooked relevant Phase 3 results that have been published in peer-reviewed journals and/or presented at internationally recognized meetings regarding the use of sofosbuvir/velpatasvir for patients with c...
Source: Journal of Hepatology - November 13, 2018 Category: Gastroenterology Authors: Luisa M. Stamm, Diana M. Brainard, John G. McHutchison Source Type: research

Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants
Hepatitis C virus (HCV) is a global health burden affecting approximately 71 million people worldwide [1]. Infection often leads to chronic hepatitis, with the subsequent risk for liver cirrhosis and hepatocellular carcinoma. Persistent HCV infection is now curable with the introduction of direct-acting antivirals (DAAs). However, a prophylactic HCV vaccine is not available. Since viral re-infection is possible and as many HCV infected individuals are not diagnosed, a vaccine against HCV would facilitate global HCV eradication programs. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 12, 2018 Category: Gastroenterology Authors: Tanvi Khera, Patrick Behrendt, Dorothea Bankwitz, Richard J.P. Brown, Daniel Todt, Mandy Doepke, Abdul Ghafoor Khan, Kai Schulze, John Law, Michael Logan, Darren Hockman, Jason Alexander Ji-Xhin Wong, Leona Dold, Victor Gonzalez-Motos, Ulrich Spengler, Ab Source Type: research

Reply to: “Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018”
The European Association for the Study of the Liver (EASL) read with interest the letter to the Editors by Stamm et al. The authors of the letter conclude that “the 12-week, single-tablet regimen of sofosbuvir/velpatasvir […] is a highly effective treatment for all patients with compensated liver disease, irrespective of genotype, extent of liver fibrosis or prior interferon treatment history”. This statement is too simplistic as the combination of s ofosbuvir and velpatasvir without ribavirin is suboptimal in patients with cirrhosis infected with HCV genotype 3 carrying the Y93H resistance-associated su...
Source: Journal of Hepatology - November 12, 2018 Category: Gastroenterology Authors: European Association for the Study of the Liver Source Type: research